Publications

Obesity is strongly linked to metabolic disorders such as type 2 diabetes, cardiovascular disease, non-alcoholic fatty liver disease, and certain cancers. The complex and progressive nature of these comorbidities requires approaches that integrate both diagnosis and treatment. Theranostic nanoplatforms engineered nanosystems capable of combining therapeutic delivery with diagnostic imaging or biomarker sensing offer a promising strategy to address this dual challenge. By enabling real-time monitoring of disease progression and simultaneous targeted therapy, these platforms enhance precision, reduce off-target toxicity, and improve treatment outcomes. Liposomes, polymeric nanoparticles, gold nanoshells, magnetic nanoparticles, and hybrid nanomaterials have been explored for theranostic applications in obesity-associated diseases. This review discusses the principles of theranostic nanoplatforms, their advances in managing obesity-related comorbidities, translational challenges, clinical perspectives, and future opportunities. These systems represent an important step toward precision nanomedicine in obesity care.